A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults
Enfuvirtide
+ Ritonavir
+ Abacavir sulfate
Infections transmises par le sang+11
+ Maladies génito-urinaires
+ Maladies Génitales
Étude thérapeutique
Résumé
Date de début de l'étude : 1 mai 1999
Date à laquelle le premier participant a commencé l'étude.Patients are assigned to one of four groups. Three dose groups receive a background antiretroviral regimen (ABC, APV, RTV, and EFV) and T-20, which is given at one of three doses on a twice-daily regimen. The fourth group (control) receives the background antiretroviral regimen alone. For each treatment group, 17 patients are enrolled. Treatment is administered for 16 weeks, followed by a 32-week treatment extension, and a 2-week follow-up period. The following are assessed throughout the trial: safety parameters (as measured by hematology, clinical chemistry, urinalysis, and treatment-emergent adverse events); virologic and immunologic activity; phenotypic and genotypic resistance; T-20 plasma levels; and pharmacokinetics of T-20 and oral antiretrovirals. The total study duration is 1 year.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.68 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have an HIV level (viral load) between 400 and 100,000 copies/ml at the screening visit. Have taken at least 1 PI (protease inhibitor) for at least 16 weeks, and have had no interruptions in their most recent PI-containing anti-HIV drug regimen. Are at least 18 years old. Agree to abstinence or use of 2 effective methods of birth control, including a barrier method, during the study. Exclusion Criteria Patients will not be eligible for this study if they: Have ever taken an NNRTI (nonnucleoside reverse transcriptase inhibitor). Have an opportunistic (HIV-related) infection. Have had an unexplained fever of at least 38.5 C for 7 days in a row within 30 days prior to screening. Have had diarrhea lasting at least 15 days within 30 days prior to screening. Have ever taken abacavir, amprenavir, or efavirenz (ABC, APV, or EFV). Have certain genetic characteristics (drug resistance mutations) that could change the way a drug acts in the body. Are allergic to any of the study medications. Have a tumor other than certain skin or cervical cancers. Are on chemotherapy that cannot be discontinued during the study. Are taking an investigational drug within 30 days prior to screening. Have ever received an HIV vaccine. Are taking certain medications. Abuse drugs or alcohol. Have hemophilia or another blood clotting disorder. Have had an organ transplant. Are pregnant or breast-feeding.
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 20 sites
UCLA Care Ctr
Los Angeles, United StatesViRx Inc
Palm Springs, United StatesDonald Northfelt
Palm Springs, United States